<DOC>
	<DOCNO>NCT00001677</DOCNO>
	<brief_summary>The safety profile efficacy combination therapy evaluate use methotrexate ( MTX ) nucleoside analog fludarabine 40 patient severe refractory rheumatoid arthritis . The patient enrol experienced inadequate disease control MTX alone combination immunosuppressive drug sulfasalazine ( SSZ ) , cyclosporin A ( CsA ) , hydroxychloroquine ( HCQ ) . In randomized , double-blind , placebo control trial , patient maintain oral MTX 17.5 mg/week either placebo subcutaneous fludarabine 30 mg/m ( 2 ) daily three consecutive day per month add four month . The fludarabine ( placebo ) treatment period follow two month follow-up , time patient evaluate response . Patients monitor adverse effects/tolerability , disease activity , change synovial volume measure magnetic resonance imaging ( MRI ) . Additionally synovial biopsy obtain treatment investigation infiltrate cell number phenotype , cytokine profile , Th1 versus Th2 response , angiogenesis .</brief_summary>
	<brief_title>Methotrexate Alone Versus Combination Methotrexate Subcutaneous Fludarabine Severe Rheumatoid Arthritis : Safety , Tolerance Efficacy</brief_title>
	<detailed_description>The safety profile efficacy combination therapy evaluate use methotrexate ( MTX ) nucleoside analog fludarabine 40 patient severe refractory rheumatoid arthritis . The patient enrol experienced inadequate disease control MTX alone combination immunosuppressive drug sulfasalazine ( SSZ ) , cyclosporin A ( CsA ) , hydroxychloroquine ( HCQ ) . In randomized , double-blind , placebo control trial , patient maintain oral MTX 17.5 mg/week either placebo subcutaneous fludarabine 30 mg/m ( 2 ) daily three consecutive day per month add four month . The fludarabine ( placebo ) treatment period follow two month follow-up , time patient evaluate response . Patients monitor adverse effects/tolerability , disease activity , change synovial volume measure magnetic resonance imaging ( MRI ) . Additionally synovial biopsy obtain treatment investigation infiltrate cell number phenotype , cytokine profile , Th1 versus Th2 response , angiogenesis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Ability provide inform consent aspect study full information provide . Age equal old 18 . A diagnosis Rheumatoid Arthritis ( RA ) 6 month define revised American College Rheumatology criterion . Active RA define : 6 swollen joint ; 6 tender joint ; ESR great 28 mm/hr ( CRP great 0.8 ) morning stiffness great 45 minute . Incomplete response ( define persistently active disease describe ) treatment least one follow regimens 3 month : MTX alone ( great equal 17.5 mg/week ) ; MTX ( great equal 17.5 mg/week ) plus HCQ ( great equal 200 mg/day ) ; MTX ( great equal 17.5 mg/week ) plus SSZ ( great equal 1 gm/d ) ; MTX ( great equal 17.5 mg/week ) plus CsA ( 13 mg/kg/day ) ; MTX ( great equal 17.5 mg/week ) plus SSZ ( great 1 gm/day ) plus HCQ ( great equal 200 mg/day ) ; No requirement corticosteroid dose equivalent 10 mg/d prednisone immunosuppressive agent require control extraarticular manifestation time study entry . No active acute chronic infection require antibiotic therapy , serious viral infection ( hepatitis , herpes zoster , HIV ) , serious fungal infection . Patients positive PPD receive INH antituberculous therapy exclude . No pregnant woman , nurse mother , patient childbearing age practice birth control . No preexist malignancy basal cell carcinoma . No history stroke , seizure disorder , chronic neurologic disease . No unstable coronary artery disease , cardiomyopathy , conduction heart block great first degree , dysrhythmia require therapy . No confound medical illness judgment investigator would pose added risk study participant ( e.g. , chronic hepatic , renal , pulmonary disease bone marrow hypoplasia ) . No presence seronegative spondyloarthropathy , systemic lupus erythematosus , systemic sclerosis , inflammatory myopathy , systemic vasculitis , psoriasis , inflammatory bowel disease . No serum creatinine great 2.0 mg/dL least 2 different occasion sustain least 1 month . No hematocrit le 28 % ( hemoglobin less 9.0 mg/dL ) , platelet count less 100,000 , white blood count less 3,500/dL . No patient active lung disease , patient chronic progressive lung disease , patient chronic stable lung disease pulmonary function test less 70 % predict ( DLCO less 60 % ) . No patient hypogammaglobulinemia ( IgG count le 300 ) . No patient treat alkylating agent 1 year time treat purine nucleoside analog time .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>Magnetic Resonance</keyword>
	<keyword>Synovial Biopsy</keyword>
	<keyword>Synovitis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>